SALSA MLPA P335 ALL-IKZF1 probemixCEimproved

application: ALL
region: IKZF1, PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A-CDKN2B, Xp22.33
[login for my products]
version: C1
sold since: 2018-04-16

item no. description price
P335-025R SALSA MLPA P335 ALL-IKZF1 probemix – 25 rxn € 237
P335-050R SALSA MLPA P335 ALL-IKZF1 probemix – 50 rxn € 474
P335-100R SALSA MLPA P335 ALL-IKZF1 probemix – 100 rxn € 948
EK1-FAM SALSA MLPA EK1 reagent kit – 100 rxn - FAM € 294
EK1-Cy5 SALSA MLPA EK1 reagent kit – 100 rxn - Cy5 € 294
EK5-FAM SALSA MLPA EK5 reagent kit – 500 rxn - FAM € 1355
EK5-Cy5 SALSA MLPA EK5 reagent kit – 500 rxn - Cy5 € 1355

Please note that both a probemix and reagent kit are needed to perform MLPA.

description
Intended use: The SALSA MLPA probemix P335 ALL-IKZF1 is an in vitro diagnostic (IVD)1 or research use only (RUO) assay for the detection of deletions in the IKZF1 gene in ALL (acute lymphoblastic leukemia) patients for patient stratification into prognostic subgroups, and a research use only (RUO) assay for the detection of deletions or duplications in B-cell differentiation and cell cycle control genes (EBF1, CDKN2A/B, PAX5, ETV6, BTG1 and RB1) and in the PAR1 region. This assay is for use on human DNA derived from peripheral blood and bone marrow, and not for use with DNA extracted from formalin-fixed paraffin embedded tumour materials.

Deletions or duplications detected by only a single probe always require validation. In the majority of patients, defects in the IKZF1 gene are deletions, but point mutations can occur which will not be detected by MLPA. It is therefore recommended to use this SALSA MLPA probemix in combination with sequence analysis of the IKZF1 gene. This assay is not intended to be used as a standalone assay for clinical decisions. The results of this test must be interpreted by a clinical molecular geneticist or equivalent.

1Please note that this probemix is for In Vitro Diagnostic use (IVD) in the countries specified at the end of this product description. In all other countries, the product is for Research Use Only (RUO).

Note that the clinical relevance of some genes in the P335 ALL-IKZF1 probemix is not yet fully established. Therefore, the CE mark for diagnostic use only applies to the IKZF1 gene, and all other genes in the probemix are meant to be used in a research setting only.

Clinical background: The overall incidence rate of ALL amounts to 1.1/100,000 per year. The peak incidence lies in childhood at an age of less than 5 years (5.3/100,000). Thereafter the incidence rate declines. In patients over 50 years it rises a second time and reaches a peak at the age of over 80 years (2.3/100,000). There is a slight predominance of males (1.4:1.0). B-ALL accounts for 76% of all cases of ALL and T-ALL accounts for the remaining 24% of cases (www.onkopedia-guidelines.info/en/onkopedia/guidelines/acute-lymphoblastic-leukemia-all/@@view/html/index.html).

Partial or complete deletions of the IKZF1 (IKAROS family zinc finger 1) gene are frequently detected in ALL cases (Mullighan et al. 2008), especially in those patients who also carry the BCR-ABL1 gene fusion (Philadelphia chromosome). IKZF1 deletions can be identified in approximately 70% of the children with Philadelphia chromosome positive (Ph+) ALL (2%-4% of all pediatric ALL cases; Bernt and Hunger 2014), in 10-15% of Philadelphia chromosome negative (Ph−) pediatric ALL and in ~40-75% of adult B-cell precursor ALL cases. Deletion of IKZF1 is associated with a poor prognosis in B-ALL patients (Mullighan et al. 2009) and a higher chance of relapse (Kuiper et al. 2010).

Several other (partial) gene deletions and duplications, such as in PAX5, ETV6, RB1, BTG1, EBF1 and CDKN2A/2B, have also been described in ALL patients. See Table 2 for more information on all genes and regions covered in this probemix.

Probemix content: This SALSA MLPA P335-C1 ALL-IKZF1 probemix contains 57 MLPA probes with amplification products between 120 and 504 nt. The probemix contains one probe for each of the 8 exons in transcript variant 1 (NM_006060.5) of the IKZF1 gene (7p12.2). In addition, it contains seven probes for PAX5 (9p13.2), six probes for ETV6 (12p13.2), five probes for RB1 (13q14.2), four probes for BTG1 and the BTG1 downstream region (12q21.33), four probes for EBF1 (5q33.3), three probes for CDKN2A-CDKN2B (9p21.3) and five probes for the Xp22.33 region (PAR1 region; SHOX area, CRLF2, CSF2RA, IL3RA and P2RY8 genes). Additionally, one probe at Yp11.31 (ZFY) and one probe at 9p24.1 (JAK2) have been included to help determine the extent of a deletion/duplication detected in patient samples. See page 4 and 5 of the product description for more information about interpretation of results of the ZFY probe. Finally, 13 reference probes have been included targeting chromosomal regions that have relatively stable copy number in ALL. The identity of the genes detected by the reference probes is available online (www.mlpa.com) and in Table 2 of the product description.

This probemix contains nine quality control fragments generating amplification products between 64 and 105 nt: four DNA Quantity Fragments (Q-fragments), two DNA Denaturation Fragments (D-fragments), one benchmark fragment, and one chromosome X- and one chromosome Y-specific fragment. More information on how to interpret observations on these control fragments can be found in the MLPA General Protocol and online at www.mlpa.com.

related products
SALSA MLPA ME024 9p21 CDKN2A/2B region probemix
Contains probes for the 9p21 region, including CDKN2A and CDKN2B for detection of both copy number and methylation status.
SALSA MLPA P047 RB1 probemix
Contains probes for 26 out of 27 exons of RB1.
SALSA MLPA P202 IKZF1 (IKAROS) probemix
Contains two probes for all exons of IKZF1, and probes for MIR31, CDKN2A/B, IKZF2, IKZF3 and the 14q32.33 region.
SALSA MLPA P327 iAMP21-ERG probemix
Contains probes for RUNX1, ERG and iAMP21 detection in ALL.
SALSA MLPA P329 CRLF2-CSF2RA-IL3RA probemix
Contains probes for CRLF2, CSF2RA, IL3RA and SHOX, involved in B-ALL.
SALSA MLPA P377 Hematologic Malignancies probemix
Contains probes for the most common copy number alterations in ALL, AML, CLL, CML, MDS and various lymphomas.
SALSA MLPA P383 T-ALL probemix
Contains probes for STIL-TAL1, LEF1, CASP8AP2, MYB, EZH2, MLLT3, MTAP, CDKN2A/B, NUP214-ABL1, PTEN, LMO1/2, NF1, SUZ12, PTPN2, PHF6, involved in T-ALL.
SALSA MLPA P419 CDKN2A/2B-CDK4 probemix
Contains probes for CDKN2A, CDKN2B and CDK4.

product history
version C1: One target probe and two reference probes have been replaced and the length of several probes has been changed.
version B2: As compared to the previous version (lot B1-1012), length of one probe has been changed.
version B1: As compared to version (lotA4-0111), several target specific probes have been replaced, one new probe has been included for PAX5 exon 7, and two new flanking probes are included for 9p and Yp arms. In addition, all the reference probes have been replaced.
version A4: The 88 and 96 nt DNA denaturation control fragments have been replaced.
version A3: The length of two probes has been increased with 1 nt.

new products
P476-ZNRF3
Adrenocortical tumours and other solid tumours
improved products
P175-Tumour Gain
Tumour Gain
P260-PALB2-RAD50-RAD51C-RAD51D
Hereditary predisposition to Cancer
P103-DPYD
Dihydropyrimidine dehydrogenase (DPYD) deficiency
P152-ABCA4 mix-2
Stargardt, Macular dystrophy, Retinitis pigmentosa, age-related macular degeneration, cone rod dystrophies
P151-ABCA4 mix-1
Stargardt, Macular dystrophy, Retinitis pigmentosa, age-related macular degeneration, cone rod dystrophies
P267-Dandy-Walker
Dandy-Walker Malformation (DWM)
P226-SDH
Paragangliomas (PGL)
P335-ALL-IKZF1
ALL
P340-EHMT1
9q subtelomeric deletion syndrome (9qSTDS) or Kleefstra syndrome.
Newsletter  |  Home  |  Site map  |  Terms and Conditions  |  Search  |  Copyright © 2018 MRC-Holland